CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 48 enrolled
Drug / intervention
anti-TNF therapy (etanercept or adalimumab)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01060098
NCT01060098N/ACompleted
CompareCT.gov

T Cells and TNF: The Impact of TNF Blockade on Effector T Cell Populations in Rheumatoid Arthritis and Other Conditions Treated With Anti-TNFalpha Agents

Imperial College London·observational·Posted Feb 2, 2010·Updated Jan 18, 2020

In Brief

An observational study evaluating anti-TNF therapy (etanercept or adalimumab) for Rheumatoid Arthritis and 2 related conditions. Completed, enrolled 48 participants across 1 site.

Detailed Summary

We aim to translate these findings into patients with rheumatoid arthritis and other conditions treated with anti-TNF (anti-tumor necrosis factor) therapy, such as psoriatic arthritis and ankylosing spondylitis. Patients from rheumatology clinics within NHS (National Health Service) trusts will be recruited. We will correlate disease activity assessed by clinical parameters, ultrasonography, and questionnaires with biomarkers in the blood and target tissues, such as synovium and skin.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
CountriesUnited Kingdom
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2, 2010
Enrollment StartApr 1, 2010
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 16.4 years ago

Interventions

anti-TNF therapy (etanercept or adalimumab)drug

Biological DMARD